NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: TORNTPHARM · data 2026-10-30
Torrent Pharmaceuticals Ltd
In plain words
Price: 12.1% below its 52-week high of ₹5,250.
Delivery: 58.9% of traded shares were kept for delivery over the last 10 sessions, against 61.6% over the last 60.
Latest results: a net profit of ₹635 cr for the quarter ended Dec 2025.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹17,400 cr |
| Net profit (last 12 months) | ₹2,124 cr |
| Sales growth, 3 years (yearly) | 12.5% |
| Profit growth, 3 years (yearly) | 20.2% |
Latest results in brief (Q3 FY26)
TORNTPHARM Q3 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹3,303 crore.
Net profit was ₹635 crore.
Operating margin was 32.9%.
EPS was ₹18.77.
TORNTPHARM के Q3 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹3,303 करोड़।
शुद्ध मुनाफ़ा: ₹635 करोड़।
ऑपरेटिंग मार्जिन: 32.9%।
EPS: ₹18.77।
TORNTPHARMના Q3 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹3,303 કરોડ.
ચોખ્ખો નફો: ₹635 કરોડ.
ઓપરેટિંગ માર્જિન: 32.9%.
EPS: ₹18.77.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 59.6% over the last 20 sessions vs 63.8% in the 40 before (0.93x); shares delivered per day 0.81x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 48 schemes hold it, about ₹1,966 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 3/15: Verdict "Single spike", sustained score 24/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 29 May 26Dividend Dividend ₹9 (ex-date) -4.1% next session
- 18 Feb 26Dividend Dividend ₹29 (ex-date) -0.8% next session
- 13 Feb 26Results Q3 FY26 results: net profit ₹635 cr +4.5% next session
- 20 Jun 25Dividend Dividend ₹6 (ex-date) 0.0% next session
- 20 May 25Results Q4 FY25 results: profit +10.9% YoY -0.4% next session
- 31 Jan 25Dividend Dividend ₹26 (ex-date) -4.5% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2025 | ₹3,303 cr | ₹635 cr | — | 32.9% | 18.77 |
| Mar 2025 | ₹2,959 cr | ₹498 cr | +10.9% | 32.6% | 14.71 |
| Sept 2024 | ₹2,889 cr | ₹453 cr | — | 32.5% | 13.37 |
| Jun 2024 | ₹2,859 cr | ₹457 cr | — | 31.6% | 13.51 |
Shareholding trend
| Holder | Jun 2025 |
|---|---|
| Promoters | 68.31% |
| Foreign institutions (FII) | 16.09% |
| Domestic institutions (DII) | 8.65% |
| Mutual funds | 4.95% |
| Retail investors | 3.19% |
| Number of shareholders | 81,856 |
Common questions
What was Torrent Pharmaceuticals Ltd's latest quarterly profit?
Torrent Pharmaceuticals Ltd reported a net profit of ₹635 cr for the quarter ended Dec 2025, on revenue of ₹3,303 cr.
How much do promoters hold in Torrent Pharmaceuticals Ltd?
Promoters held 68.31% of Torrent Pharmaceuticals Ltd at the end of Jun 2025, with 0.00% of promoter shares pledged.
Is Torrent Pharmaceuticals Ltd debt-free?
Its latest reported debt-to-equity ratio is 1.79, meaning borrowings are larger than shareholders' equity.
What is Torrent Pharmaceuticals Ltd's P/E ratio?
About 75.6, based on the last 12 months' earnings and a price of ₹4,613.4 (data 2026-10-30).
What is the 52-week high and low of Torrent Pharmaceuticals Ltd?
The 52-week high is ₹5,250 and the 52-week low is ₹3,532.6.
Mutual funds holding Torrent Pharmaceuticals Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 48 schemes holding about ₹1,966 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 4.42% | ₹260 cr |
| NIPPON INDIA ETF NIFTY NEXT 50 JUNIOR BEES | Nippon India Mutual Fund | 2.89% | ₹250 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 6.80% | ₹238 cr |
| NIPPON INDIA VALUE FUND | Nippon India Mutual Fund | 1.58% | ₹134 cr |
| Nippon India Flexi Cap Fund | Nippon India Mutual Fund | 1.40% | ₹129 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 7.16% | ₹124 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 9.28% | ₹100 cr |
| ADITYA BIRLA SUN LIFE MULTI ASSET ALLOCATION FUND | Aditya Birla Sun Life Mutual Fund | 1.20% | ₹90 cr |
| ADITYA BIRLA SUN LIFE QUANT FUND | Aditya Birla Sun Life Mutual Fund | 4.55% | ₹84 cr |
| SBI Nifty Next 50 ETF | SBI Mutual Fund | 2.89% | ₹84 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.44% | ₹84 cr |
| SBI Nifty Next 50 Index Fund | SBI Mutual Fund | 2.91% | ₹67 cr |
| Nippon India Nifty Alpha Low Volatility 30 Index Fund | Nippon India Mutual Fund | 4.73% | ₹55 cr |
| Mirae Asset Nifty Next 50 ETF | Mirae Asset Mutual Fund | 2.89% | ₹42 cr |
| ADITYA BIRLA SUN LIFE BUSINESS CYCLE FUND | Aditya Birla Sun Life Mutual Fund | 2.23% | ₹39 cr |
Similar companies
Divi's Laboratories Limited (DIVISLAB) · Laurus Labs Ltd. (LAURUSLABS) · Zydus Lifesciences Limited (ZYDUSLIFE) · Dr. Reddy's Laboratories Ltd. (DRREDDY) · Mankind Pharma Ltd. (MANKIND)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open TORNTPHARM in NSE Scanner →